Inozyme Pharma (INZY)
US Market

Inozyme Pharma (INZY) Stock Price & Analysis


INZY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.99 - $7.24
Previous Close$6.43
Average Volume (3M)753.21K
Market Cap
Enterprise Value$178.88M
Total Cash (Recent Filing)$130.93M
Total Debt (Recent Filing)$26.66M
Price to Earnings (P/E)-4.0
Sep 07, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding44,035,322
10 Day Avg. Volume466,934
30 Day Avg. Volume753,208
Standard Deviation0.34
Financial Highlights & Ratios
Price to Book (P/B)2.68
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.54
Price Target Upside205.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Inozyme Pharma’s price range in the past 12 months?
Inozyme Pharma lowest stock price was $0.99 and its highest was $7.24 in the past 12 months.
    What is Inozyme Pharma’s market cap?
    Currently, no data Available
    When is Inozyme Pharma’s upcoming earnings report date?
    Inozyme Pharma’s upcoming earnings report date is Sep 07, 2023 which is in 96 days.
      How were Inozyme Pharma’s earnings last quarter?
      Inozyme Pharma released its earnings results on May 09, 2023. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.446 by $0.046.
        Is Inozyme Pharma overvalued?
        According to Wall Street analysts Inozyme Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Inozyme Pharma pay dividends?
          Inozyme Pharma does not currently pay dividends.
          What is Inozyme Pharma’s EPS estimate?
          Inozyme Pharma’s EPS estimate is -$0.44.
            How many shares outstanding does Inozyme Pharma have?
            Inozyme Pharma has 44,035,320 shares outstanding.
              What happened to Inozyme Pharma’s price movement after its last earnings report?
              Inozyme Pharma reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.446. Following the earnings report the stock price went up 9.532%.
                Which hedge fund is a major shareholder of Inozyme Pharma?
                Among the largest hedge funds holding Inozyme Pharma’s share is Deerfield Management Company, LP. It holds Inozyme Pharma’s shares valued at N/A.


                  Inozyme Pharma Stock Smart Score

                  The Inozyme Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Inozyme Pharma

                  Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.


                  Top 5 ETFs holding INZY

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold INZY. The ETFs are listed according to market value of INZY within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Bioxcel Therapeutics
                  Crinetics Pharmaceuticals
                  Adaptimmune Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis